5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
BFI Co., LLC, a ten percent owner of Phibro Animal Health Corp (NASDAQ:PAHC), sold 16,775 shares of Class A Common Stock between October 17 and October 20, 2025. The sales, executed under a pre-arranged Rule 10b5-1 trading plan, generated $677,198. The transaction comes as PAHC trades near its 52-week high of $41.57, having delivered an impressive 142% return over the past six months.
The transactions occurred at prices ranging from $40.00 to $40.59. Specifically, on October 17, 700 shares were sold at a weighted average price of $40.0319, with prices ranging from $40.00 to $40.07. On October 20, 16,075 shares were sold at a weighted average price of $40.3842, with prices ranging from $40.00 to $40.59.
Additionally, on October 21, BFI Co., LLC acquired 50,000 shares of Class A Common Stock upon conversion of Class B Common Stock, with the price per share at $0.0. Following these transactions, BFI Co., LLC directly holds 23,899 shares.
Jack Bendheim, a director, officer, and ten percent owner of Phibro Animal Health Corp (NASDAQ:PAHC), may be deemed to have shared voting and investment power over the securities held by BFI Co., LLC. He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Bendheim directly holds 16,840 shares of Class A Common Stock. He also indirectly holds 20,086,034 shares of Class B Common Stock, each convertible into Class A Common Stock. For deeper insights into insider trading patterns and comprehensive analysis, access the full PAHC research report on InvestingPro, where you’ll find 10+ additional ProTips and detailed financial metrics.
In other recent news, Phibro Animal Health Corporation reported impressive fourth-quarter 2025 financial results, surpassing expectations with an earnings per share (EPS) of $0.57, compared to the forecasted $0.52. The company’s revenue also exceeded predictions, reaching $378.7 million against an anticipated $362.24 million. In addition to strong earnings, Phibro has secured exclusive worldwide rights to develop and market a novel therapeutic compound for canine periodontal disease through a licensing agreement with Lighthouse Pharmaceuticals, Inc. This agreement highlights Phibro’s efforts to expand its product offerings in the animal health sector. BNP Paribas Exane responded to these developments by raising its price target for Phibro Animal Health to $37, up from $24, while maintaining a Neutral rating on the stock. The research firm noted the company’s strong revenue growth and margin expansion momentum. These recent developments reflect Phibro’s positive trajectory in both financial performance and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.